Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) EBIT Margin (2019 - 2025)

Historic EBIT Margin for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to 1513.47%.

  • Avidity Biosciences' EBIT Margin rose 26874700.0% to 1513.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 2934.9%, marking a year-over-year increase of 2744500.0%. This contributed to the annual value of 3477.43% for FY2024, which is 10130200.0% down from last year.
  • Avidity Biosciences' EBIT Margin amounted to 1513.47% in Q3 2025, which was up 26874700.0% from 4448.71% recorded in Q2 2025.
  • Avidity Biosciences' EBIT Margin's 5-year high stood at 882.29% during Q1 2021, with a 5-year trough of 8360.9% in Q1 2025.
  • In the last 5 years, Avidity Biosciences' EBIT Margin had a median value of 2125.76% in 2022 and averaged 2731.32%.
  • The largest annual percentage gain for Avidity Biosciences' EBIT Margin in the last 5 years was 26874700bps (2025), contrasted with its biggest fall of -61823300bps (2025).
  • Avidity Biosciences' EBIT Margin (Quarter) stood at 2081.37% in 2021, then grew by 8bps to 1922.17% in 2022, then crashed by -58bps to 3043.46% in 2023, then tumbled by -34bps to 4069.63% in 2024, then soared by 63bps to 1513.47% in 2025.
  • Its EBIT Margin was 1513.47% in Q3 2025, compared to 4448.71% in Q2 2025 and 8360.9% in Q1 2025.